253 related articles for article (PubMed ID: 26801910)
1. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
2. Transduction of yeast cytosine deaminase mediated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine.
Lee H; Ryu J; Kim KA; Lee KS; Lee JY; Park JB; Park J; Choi SY
Exp Mol Med; 2004 Feb; 36(1):43-51. PubMed ID: 15031670
[TBL] [Abstract][Full Text] [Related]
3. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Kievit E; Nyati MK; Ng E; Stegman LD; Parsels J; Ross BD; Rehemtulla A; Lawrence TS
Cancer Res; 2000 Dec; 60(23):6649-55. PubMed ID: 11118048
[TBL] [Abstract][Full Text] [Related]
4. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
[No Abstract] [Full Text] [Related]
5. Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
Zamboni S; Mallano A; Flego M; Ascione A; Dupuis ML; Gellini M; Barca S; Cianfriglia M
Int J Oncol; 2008 Jun; 32(6):1245-51. PubMed ID: 18497986
[TBL] [Abstract][Full Text] [Related]
6. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.
Lan KH; Shih YS; Chang CA; Yen SH; Lan KL
Biochem Biophys Res Commun; 2012 Nov; 428(2):292-7. PubMed ID: 23085230
[TBL] [Abstract][Full Text] [Related]
7. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
[TBL] [Abstract][Full Text] [Related]
8. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
Hamstra DA; Rice DJ; Fahmy S; Ross BD; Rehemtulla A
Hum Gene Ther; 1999 Aug; 10(12):1993-2003. PubMed ID: 10466633
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Yi BR; Kim SU; Kim YB; Lee HJ; Cho MH; Choi KC
Oncol Rep; 2012 Jun; 27(6):1823-8. PubMed ID: 22426744
[TBL] [Abstract][Full Text] [Related]
10. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Altanerova U; Jakubechova J; Benejova K; Priscakova P; Repiska V; Babelova A; Smolkova B; Altaner C
Int J Cancer; 2021 Jan; 148(1):128-139. PubMed ID: 32621791
[TBL] [Abstract][Full Text] [Related]
11.
Al-Mansoori L; Bashraheel SS; Qahtani ADA; O'Connor CD; Elsinga P; Goda SK
Oncotarget; 2020 Feb; 11(6):619-633. PubMed ID: 32110281
[TBL] [Abstract][Full Text] [Related]
12. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
13. Regional delivery and selective expression of a high-activity yeast cytosine deaminase in an intrahepatic colon cancer model.
Zhang M; Li S; Nyati MK; DeRemer S; Parsels J; Rehemtulla A; Ensminger WD; Lawrence TS
Cancer Res; 2003 Feb; 63(3):658-63. PubMed ID: 12566311
[TBL] [Abstract][Full Text] [Related]
14. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
15. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
17. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model.
Graepler F; Lemken ML; Wybranietz WA; Schmidt U; Smirnow I; Gross CD; Spiegel M; Schenk A; Graf H; Lauer UA; Vonthein R; Gregor M; Armeanu S; Bitzer M; Lauer UM
World J Gastroenterol; 2005 Nov; 11(44):6910-9. PubMed ID: 16437592
[TBL] [Abstract][Full Text] [Related]
18. Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein.
Lears KA; Parry JJ; Andrews R; Nguyen K; Wadas TJ; Rogers BE
Cancer Gene Ther; 2015 Mar; 22(4):215-21. PubMed ID: 25837665
[TBL] [Abstract][Full Text] [Related]
19. 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene.
Fuerer C; Iggo R
Gene Ther; 2004 Jan; 11(2):142-51. PubMed ID: 14712298
[TBL] [Abstract][Full Text] [Related]
20. Product release is rate-limiting in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Yao L; Li Y; Wu Y; Liu A; Yan H
Biochemistry; 2005 Apr; 44(15):5940-7. PubMed ID: 15823054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
